The Rosen Law Firm announces that it is investigating the Board of Directors of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) for possible breaches of fiduciary duty and other violations of law by failing to adequately shop NPS Pharmaceuticals to maximize shareholder value before agreeing to be acquired by Shire plc (LSE: SHP, NASDAQ: SHPG).

If you would like to join the action, go to or contact Phillip Kim or Kevin Chan, toll-free at 866-767-3653, or via e-mail at or There is no cost or obligation to you.

Under the terms of the proposed transaction, shareholders will receive $46.00 in cash for each share of NPS Pharmaceuticals they own. The proposed transaction is valued at approximately $5.2 billion. The investigation relates to whether the proposal is fair to the public shareholders of NPS Pharmaceuticals and whether NPS Pharmaceuticals' Board breached its fiduciary duties in connection with the proposed sale.

If you currently own shares of NPS Pharmaceuticals and wish to obtain additional information, please visit the website at You may also contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010